• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Pfizer blocking research to generate evidence on optimal use of novel antiviral for COVID-19 patients in low- and middle-income countries

Geneva / New York — 15 Mar 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • Deutsch
    • English
    • Français

The Drugs for Neglected Diseases initiative (DNDi), on behalf of a consortium of 26 African and global research organizations, expressed concern today that efforts to conduct urgently needed studies in low- and middle-income countries (LMICs) utilizing the novel oral antiviral, nirmatrelvir/ritonavir (Paxlovid), are being blocked by Pfizer, which developed the drug.

Nirmatrelvir/ritonavir has emerged as one of the most promising antiviral treatments for outpatients with mild-to-moderate COVID-19, reducing the risk of hospitalization or death by up to 89% in patients at high risk of severe disease.[1] This and other novel oral antiviral treatments will be a critical part of the therapeutic arsenal to treat patients today and prepare for future waves. However, the treatment must be taken within 3-5 days of symptom onset to be effective and reaching patients this early in the course of their infection is challenging.

But an interim analysis done in the context of the ongoing ANTICOV clinical trial conducted in 10 African countries showed that of the 1,180 patients enrolled, more than half present for care after day 5 (mean 5.1 days, median 5.0 days). This means that even in a clinical trial setting, more than half of patients would not benefit from nirmatrelvir/ritonavir.

To overcome this challenge, it is necessary to explore whether using nirmatrelvir/ritonavir with other drugs could widen the ‘treatment window’ to at least 7 days and be beneficial for immune-suppressed patients who are the most vulnerable to disease progression but were excluded from phase 3 trials (as such, there is no robust evidence available to guide the therapeutic strategies).

DNDi and academic investigators from large university hospitals in Europe have separately approached Pfizer about potential collaborations on combination studies in LMICs but Pfizer has declined to provide access to the drug for research purposes.

‘There are critically important public health research questions that must be answered quickly – particularly in low- and middle-income countries where access to vaccines remains low,’ said Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response and one of the coordinators of the ANTICOV Consortium. ‘It is difficult to understand any rationale for refusing to cooperate in the midst of a global pandemic, and this sets a dangerous precedent since there are many other promising antivirals in the pipeline and these novel treatments will also require follow-on research to determine their optimal use in resource-limited settings.’

DNDi is also concerned about additional hurdles in obtaining generic versions of the drug to conduct the relevant combination studies via ANTICOV. For example:

  • The terms of the Pfizer/Medicines Patent Pool (MPP) licensing agreement could be interpreted to mean that sub-licensees cannot provide nirmatrelvir/ritonavir for use in the sorts of combination studies that DNDi and others wish to conduct, unless they have explicit written approval from Pfizer.[2]
  • Some generic manufacturers are also encountering difficulties obtaining Paxlovid as a ‘reference drug’ so that they can conduct the necessary bioequivalence studies to show regulators that their generic version has the same effect in the body, effectively blocking availability of generics for both research and clinical use.

‘Every effort should be made to ensure that clinical studies for COVID-19 treatment are conducted in low- and middle-income countries, and that any products developed reach vulnerable populations,’ said Dr John Amuasi, Leader, Global Health and Infectious Diseases Research Group, Kumasi Center for Collaborative Research in Tropical Medicine in Ghana and a principal investigator for ANTICOV. ‘We must not arrive at a situation where research priorities are determined by the actions or inactions of any company.’

DNDi, the ANTICOV Consortium, and other clinical researchers therefore ask Pfizer to:

  1. Agree to provide access to nirmatrelvir/ritonavir (Paxlovid) for the DNDi-coordinated ANTICOV trial and other relevant clinical trials;
  2. Remove any ambiguities or restrictions in the Pfizer-MPP licensing agreement that could prevent sub-licensees from supplying such research studies (or publicly clarify that no such restrictions exist);
  3. Provide access to Pfizer’s originator product as a ‘reference drug’ so that any interested generic manufacturer can conduct the necessary bioequivalence studies for regulatory approval; and
  4. Allocate sufficient quantities of Paxlovid specifically for LMICs and remove all barriers to access to generic nirmatrelvir/ritonavir to enable scale up for care and treatment in LMICs.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low- and middle-income countries. Since its inception in 2003, DNDi has delivered nine new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contacts 

Frédéric Ojardias (Geneva) 
fojardias@dndi.org
+41 79 431 62 16  

Ilan Moss (New York) 
imoss@dndi.org 
+1 646 266 5216 


[1] See FDA News Release, December 22, 2021: Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 | FDA

[2] Pfizer-MPP License and Sublicense (Execution Version), November 2021.

Policy advocacy COVID-19

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License